Why the study?
Does intravenous procainamide modify the relationship between surface ECG morphology and endocardial breakthrough sites in a canine model of recurrent monomorphic VT?
Does intravenous procainamide modify the relationship between surface ECG morphology and endocardial breakthrough sites in a canine model of recurrent monomorphic VT?
Similar surface ECG morphologies of recurrent VT strongly predict closely spaced endocardial breakthrough sites in a drug-free state, but this predictive value is lost after procainamide administration.
No takes yet. Share an insight, caveat, or question.
Procainamide may disrupt ECG-based VT localization in canines; leaves open relevance to clinical mapping accuracy.
Osswald et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: